Bristol Myers Squibb picks Generation Park for $2.3B Houston plant

Bristol Myers Squibb will build a $2.3 billion pharmaceutical manufacturing campus at Generation Park, McCord Development’s 4,300-acre master-planned hub in northeast Houston. The roughly 600,000-square-foot facility will produce small-molecule drugs, biologics and antibody-drug conjugates, and the company says it is designed as a modular, multi-modal campus that can add manufacturing lines as demand shifts rather than being built for a single product line.

Why it matters

For developers and GCs chasing life-sciences work, the site-selection choice is the story as much as the dollar figure. BMS did not build a from-scratch industrial park. It bought into an existing 4,300-acre master-planned development with entitlements, utilities and rail and highway access already in place, a pattern that favors landowners who control shovel-ready parcels inside established parks over raw greenfield sites. The deal also lands squarely in the industrial-manufacturing reshoring wave developers have been positioning for, with a Fortune 500 pharma name validating Houston as a life-sciences manufacturing location alongside its existing energy and petrochemical base. More on the market at our Houston hub.

The numbers

BMS is putting $2.3 billion into the campus, part of the company’s previously announced $40 billion, five-year commitment to U.S. research, technology and domestic manufacturing. The Houston project is expected to create nearly 500 permanent skilled jobs spanning operations, production, maintenance, engineering and quality control, plus approximately 2,000 construction and indirect jobs between 2027 and 2030. CEO Christopher Boerner said the investment “reflects our confidence in America’s continued leadership in biopharmaceutical innovation.”

What’s next

Construction is slated to run 2027 through 2030, with the campus scaling in phases after that as BMS brings additional manufacturing lines online. Watch for Harris County or state of Texas incentive filings tied to the project, and for whether Generation Park lands a second life-sciences tenant now that a name-brand pharma anchor has committed.